A booster dose of Johnson & Johnson's COVID-19 vaccine sharply increased levels of antibodies against the coronavirus, according to interim data from two small, early-stage trials, the company said in a press release on Wednesday.

สล็อตxoใหม่ are gambling games with reasonable risks. But it's worth a try. So, if your friends win the Jackpot by investing a few hundred will receive a profit back up to hundreds of thousands May make friends become millionaires in the blink of an eye. SLOTXO bets depend on your friends, but it's not strange.

J&J has been under pressure to produce evidence of whether a booster shot would increase protection from its one-shot vaccine as the US government prepares to roll out a booster campaign next month. The company plans to discuss the data with US regulators as they devise their booster shot regimens.

The preliminary data announced on Wednesday involved a total of 17 people. It found that a second dose of the J&J vaccine delivered six months after the first resulted in a ninefold increase in binding antibody levels over those seen 28 days after the first dose, the company said.

The company did not release data on whether a second dose of its vaccine increases levels of neutralizing antibodies, which block the virus from entering cells.

Those data are still being analyzed, said Dr Dan Barouch, a Harvard vaccine researcher who helped design J&J’s COVID-19 vaccine, but who was not involved in the J&J booster study.

Unlike neutralizing antibodies, binding antibodies tag the virus for destruction by other parts of the immune system. Barouch said increases in binding antibodies typically correlate with increases in neutralizing antibodies.